Achilles Therapeutics plc

NasdaqCM:ACHL Stock Report

Market Cap: US$44.0m

Achilles Therapeutics Management

Management criteria checks 2/4

Achilles Therapeutics' CEO is Iraj Ali, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $1.70M, comprised of 27.3% salary and 72.7% bonuses, including company stock and options. directly owns 2.71% of the company’s shares, worth $1.19M. The average tenure of the management team and the board of directors is 5.4 years and 4.5 years respectively.

Key information

Iraj Ali

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage27.3%
CEO tenure6.8yrs
CEO ownership2.7%
Management average tenure5.4yrs
Board average tenure4.5yrs

Recent management updates

Recent updates

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Sep 20
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 13
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Jul 19
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Mar 11
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 18
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles-led group gets €4M funding for personalized cell therapy manufacturing

Jul 21

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Apr 13
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Dec 27
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

CEO Compensation Analysis

How has Iraj Ali's remuneration changed compared to Achilles Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$67m

Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$64m

Dec 31 2023US$2mUS$463k

-US$70m

Compensation vs Market: Iraj's total compensation ($USD1.70M) is above average for companies of similar size in the US market ($USD646.00K).

Compensation vs Earnings: Insufficient data to compare Iraj's compensation with company performance.


CEO

Iraj Ali (49 yo)

6.8yrs

Tenure

US$1,698,000

Compensation

Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....


Leadership Team

NamePositionTenureCompensationOwnership
Iraj Ali
CEO & Director6.8yrsUS$1.70m2.71%
$ 1.2m
Sergio Quezada
Founder & Chief Scientific Officer8.8yrsno data1.12%
$ 494.9k
Robert Coutts
Chief Financial Officer4yrsno data0.66%
$ 288.9k
Mark Lowdell
Founder & Member of Scientific Advisory Board8.8yrsno datano data
Charles Swanton
Founder & Member of Scientific Advisory Board8.8yrsno datano data
Lee Stern
Vice President of Investor Relations & External Communications3.9yrsno datano data
Daniel Carey Hood
General Counsel & Company Secretary2yrsno datano data
Julia Wilson
Head of Communicationsno datano datano data
Tariq Ahmed
Executive Vice President of Peopleno datano datano data
Edward Samuel
Executive Vice President of Technical Operationsno datano datano data
Shree Patel
Executive Vice President of Supply Operationsno datano datano data
James A. Taylor
Chief Business Officer2.8yrsno datano data

5.4yrs

Average Tenure

50.5yo

Average Age

Experienced Management: ACHL's management team is seasoned and experienced (5.4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Iraj Ali
CEO & Director8.7yrsUS$1.70m2.71%
$ 1.2m
Mark Lowdell
Founder & Member of Scientific Advisory Boardless than a yearno datano data
Charles Swanton
Founder & Member of Scientific Advisory Boardless than a yearno datano data
Edwin Moses
Independent Chairman of the Board5.9yrsUS$379.00k0.55%
$ 242.4k
Carsten Boess
Independent Non-Executive Director4.6yrsUS$176.00k0%
$ 0
Markwin Velders
Member of Scientific Advisory Board3.5yrsno datano data
Scott Antonia
Member of Scientific Advisory Board4.5yrsno datano data
Michael Giordano
Independent Non-Executive Director6.2yrsUS$189.00k0.11%
$ 50.0k
Karl Peggs
Founder & Member of Scientific Advisory Boardless than a yearno data1.36%
$ 600.2k
Elizabeth Jaffee
Member of Scientific Advisory Board4.5yrsno datano data
Christopher Klebanoff
Member of Scientific Advisory Board4.5yrsno datano data
Alena Gros
Member of Scientific Advisory Board2.8yrsno datano data

4.5yrs

Average Tenure

58yo

Average Age

Experienced Board: ACHL's board of directors are considered experienced (4.5 years average tenure).